Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets open firm
Mon, 2 Apr 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in Japan (up 0.7%) and Indonesia (up 0.7%) leading the gains. However, markets in Taiwan (down 0.6%) and Hong Kong (down 0.3%) are facing selling pressure. The Indian stock markets have opened the day on a firm note. Stocks in the consumer durables and power space are leading the gains. However, oil and gas stocks are trading in the red.

The BSE-Sensex is trading up by 60 points (0.3%), while the NSE-Nifty is up by around 14 points (0.3%). Mid cap and small cap stocks are also trading in the green, with the BSE Mid cap and BSE Small cap indices up by 0.9% and 1% respectively. The rupee is trading at Rs 50.82 to the US dollar.

Auto stocks have opened the day on a mixed note with Tata Motors (Telco) and Ashok Leyland trading firm. However, Bajaj Auto and Hero MotoCorp are facing selling pressure. India's largest commercial vehicle maker, Tata Motors has raised the selling prices of some of the vehicles in the commercial vehicles (CV) category. The company said that the price increase will be in the range of Rs 5,000 to 60,000. This comes after the hike in the excise duty in the recent Union Budget 2012-13. The new prices will be effective from March 17, 2012. The price increases are in the range of 2%-5% in the CV categories. The company expects the near term sales to get affected due to the price hikes. However, the sales growth should come back on track once the consumers adjust to this hike. The company expects 18%-19% increase in commercial vehicle sales in 2011-12.

Pharma stocks have opened the day on a mixed note with Aurobindo Pharma and Ranbaxy Laboratories trading in the red. However, Strides Arcolab and Dishman Pharma are trading firm. Leading Indian drugmaker Ranbaxy Laboratories is close to capturing 50% market share in the atorvastatin market in the US during the six-month exclusive marketing period. The company sells the low-cost version of Lipitor, the anti-cholesterol drug. As per latest data released by drug market research firm IMS Health, Ranbaxy has been able to lift up its market share from 41% as on February 3 to 45% as on March 16. Watson Pharmaceuticals, Pfizer's generic partner has a little over 20% share. Pfizer Ltd accounts for rest of the market share. It must be noted that Lipitor is the world's best-selling brand with annual sales of about US$ 7.9 bn in the US market alone. Ranbaxy is selling its drug at about 60-70% discount to Lipitor.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.